ZNTL Zentalis Pharmaceuticals, Inc.
Research report · from SEC EDGAR · close 2026-07-14
$4.77 +3.2%
$339.6M mkt cap
executive summary
Zentalis Pharmaceuticals, Inc. (ZNTL) is a $339.6M company. Revenue is $0 (-100.0% y/y). It is not yet profitable. Our health score is F (34/100). 4 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$0
-100.0% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-3.82).
⚠Weak fundamentals
Piotroski F-Score of 2/9 — most quality checks are failing.
⚠One-sided insider selling
4 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 4
Cash & ST investments
$31.9M
Operating cash flow
-$125.2M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-14 by stocktools.ai.